26 / 27
Cherny NI.
Annals of Oncology 26: 1547–1573, 2015;
Cherny NI.
Annals of Oncology 28: 2340–2366, 2017.
Lenvatinib is scored as high level of proven clinical
benefit by ESMO-MCBS
ü
The ESMO-MCBS is a validated and reproducible
tool to assess the magnitude of clinical benefit
from new cancer therapies.
high level of proven
clinical benefit
ESMO-MCBS: European Society of Molecular Ooncology - Magnitude of Clinical Benefit Scale.